Understanding Suboptimal Response to Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Understanding Suboptimal Response to Immune Checkpoint Inhibitors

Published:2022-03-27 Issue:4 Volume:7 Page:
ISSN:2701-0198
Container-title:Advanced Biology
language:en
Short-container-title:Advanced Biology

Author:

Zhu Mojun¹,Zhang Henan²,Pedersen Katrina S.³,Foster Nathan R.⁴,Jaszewski Brandy L.⁴,Liu Xin²,Hirdler Jacob B.²,An Zesheng²,Bekaii‐Saab Tanios S.⁵,Halfdanarson Thorvardur R.¹,Boland Patrick M.⁶,Yan Yiyi¹,Hubbard Joleen H.¹,Ma Wen Wee¹,Yoon Harry H.¹,Revzin Alexander⁷,Fernandez‐Zapico Martin E.¹,Overman Michael J.⁸,McWilliams Robert R.¹,Dong Haidong²^ORCID

Affiliation:

1. Medical Oncology Mayo Clinic Rochester MN 55905 USA

2. Urology and Immunology Mayo Clinic Rochester MN 55905 USA

3. Division of Oncology Washington University St. Louise MO 63110 USA

4. Division of Biomedical Statistics and Informatics Mayo Clinic Rochester MN 55905 USA

5. Division of Hematology/Oncology Mayo Clinic Phoenix AZ 85054 USA

6. Rutgers Cancer Institute of New Jersey New Brunswick NJ 08901 USA

7. Physiology and Biomedical Engineering Mayo Clinic Rochester MN 55905 USA

8. MD Anderson Cancer Center Houston TX 77030 USA

Funder

Center for Individualized Medicine, Mayo Clinic

Publisher

Wiley

Subject

General Biochemistry, Genetics and Molecular Biology,Biomedical Engineering,Biomaterials

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adbi.202101319

Reference37 articles.

1. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

2. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma

3. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

4. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

5. Cancer immunoediting and resistance to T cell-based immunotherapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial;Nature Communications;2024-02-16

2. Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery;Urologic Oncology: Seminars and Original Investigations;2023-09

3. CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through NF-κB signaling pathway in ankylosing spondylitis in vitro;Journal of Translational Medicine;2023-08-25

4. The Mechanisms of Ferroptosis and the Applications in Tumor Treatment: Enemies or Friends?;Frontiers in Molecular Biosciences;2022-07-15

5. Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer;Frontiers in Oncology;2022-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3